Live Breaking News & Updates on Elara Study

Stay updated with breaking news from Elara study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting. ....

Stephenj Schuster , Margarita Louis Dreyfus Professor , Chronic Lymphocytic Leukemia , Lymphoma Clinical Care , Follicular Lymphoma , Elara Study , Relapsed Refractory Follicular Lymphoma ,